Regan Miles was named Vice Chairman of Unigen, Inc. effective August 1, 2021. His transition from President & CEO to Vice Chairman is fundamental to the company’s succession planning and positioning for the future and rapid growth of Unigen.
Mr. Miles began his career with Unigen in 2002 as EVP of Sales & Marketing. He served two terms as Unigen’s President and CEO, from 2006-2008 and 2015-2021. During his time with Unigen, Mr. Miles has been instrumental in growing the business from a new research and development firm to a profitable patented ingredient supplier. Under his leadership the biotech company launched 10 proprietary branded ingredients that ultimately brought to fruition the vision and mission of “Bringing the best of nature to humankind.”
Mr. Miles has 30+ years of experience in the natural products industry. He has held top leadership positions with many of the leading companies in the industry including Nature’s Way, Pharmanex, Integrative Therapeutics, Univera and Next Pharmaceuticals. He has demonstrated a strong record of success in achieving growth and profitability at the companies he has been associated with. As Vice Chairman, Mr. Miles shares his industry knowledge, working in collaboration and mentoring Unigen’s new executive leadership.
President & CEO
Rodney E. Storms, JD
Vice President, Sales & Marketing
Rodney E. Storms was named Vice President, Sales & Marketing, Unigen, Inc., effective August 1, 2021. Mr. Storms, worked for the company for 15 years. The promotion to Vice President, Sales & Marketing is part of Unigen’s succession planning and positioning for its future and rapid growth.
Since joining Unigen as Regional Sales Manager in 2005, Mr. Storms has been very instrumental in establishing key customer accounts for our Patented Products. In addition, Mr. Storms, helped established many key Clinical collaborations with potential customers, which saved Unigen large financial investments, and created immediate customers. Also, Mr. Storms, is very instrumental in bringing in many PhytoLogix® deals over the years, helping to establish our Plant Library Platform as one of the best globally. Mr. Storms was the Director of Regional Sales Manager from 2016-2021.
Mr. Storms received his B.A. in Political Science and an independent B.A. in Sociology from The University of Texas at San Antonio. He followed his undergraduate work with a Juris Doctorate at The Columbus School of Law, Catholic University of America. Prior to joining Unigen, Mr. Storms was the Director of Membership and Interim President, American Herbal Products Association (AHPA).
As Vice President, Sales & Marketing, Mr. Storms will lead Unigen Sales & Marketing Team through substantial growth and diversification via products, customers, channel of business and continue to fulfill its global vision of “Bringing the best of nature to humankind.”
VP of Operations
Vice President of Clinical Research and Regulatory Compliance
Vice President, General Counsel, and Secretary
ECONET (Unigen’s parent company)
Casey Harris is a member of ECONET’s executive team and has been with the ECONET family of companies since 2011. He serves as Unigen’s generalist legal counsel with experience in the retail industry, including regulation of cosmetics/dietary supplements (FDA). Specialties include regulatory advisement, intellectual property, private corporate governance, and general business legal advisement. Mr. Harris received his Juris Doctor degree from Lewis & Clark Law School, with a focus on intellectual property law. He received his Bachelor’s degree in Chemistry from Brigham Young University and will receive an MBA from the University of Illinois at Urbana-Champaign in December 2022.
Mesfin Yimam, DVM, MS.
Director, Pre-Clinical Research
Dr. Mesfin Yimam joined Unigen in December 2004, with practical experience in pharmaceutical research and veterinary medicine. Dr. Yimam is a board certified DVM. He received his doctorate degree in veterinary medicine from Addis Ababa University, Ethiopia. He further broadened his knowledge in the field of drug discovery by studying pharmaceutics and has acquired his master’s degree at the University of Washington in Seattle, where he focused on identifying and characterizing primate P-gp and illustrating target specific drug delivery in syngeneic experimental brain tumor model.
Dr. Yimam currently holds a director position leading the Pre-Clinical Development team at Unigen. His research interest is primarily focused on the discovery of natural products based novel dietary ingredients for osteoarthritis, metabolic disorders, sleep, brain health and immunity. Over the years, he has made significant contribution in multiple projects through development and validation of several in vivo disease models; optimization of in vivo experiments to support safety, efficacy, mechanism of actions and pharmacokinetics studies, ensuring research strategy and procedures in compliance with regulations and organization guidelines pursuant to FDA and other regulatory agencies. Dr. Yimam has published more than 40 peer reviewed articles, co-invented several issued and pending patents, presented his work in a range of scientific conferences and is also an editorial board member and invited reviewer for reputable journals for scientific publications.